R. Weitzman

A national study on lipid management.

V. Novack, A. Jotkowitz, A. Porath, 2008, European journal of internal medicine.

Do patients with diabetes and low socioeconomic status receive less care and have worse outcomes? A national study.

L. Epstein, A. Jotkowitz, A. Porath, 2006, The American journal of medicine.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

T. Mikkelsen, M. Prados, P. Wen, 2017, Neuro-oncology.

Estimation of mortality savings due to a national program for diabetes care.

J. Dreiher, A. Porath, G. Rabinowitz, 2009, European journal of internal medicine.

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

David C. Smith, R. Berger, R. Kurzrock, 2017, European journal of cancer.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

T. Mikkelsen, M. Prados, P. Wen, 2018, Neuro-oncology.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

T. Mikkelsen, M. Prados, P. Wen, 2017, Neuro-oncology.